Peptide Nasal Sprays — Complete Guide to Intranasal Delivery

Intranasal delivery is the preferred administration route for several peptides — particularly those targeting the central nervous system. Unlike subcutaneous injection, nasal sprays can bypass the blood-brain barrier entirely, delivering peptides directly to the brain via the olfactory and trigeminal pathways. This guide covers the science, practical preparation, and considerations for nasal peptide use.

Why intranasal delivery?

The olfactory pathway to the brain

The nasal cavity provides unique access to the CNS through two anatomical routes:

Olfactory nerve pathway: The olfactory epithelium in the upper nasal cavity contains olfactory receptor neurons whose axons project directly through the cribriform plate into the olfactory bulb. Molecules deposited on this epithelium can travel along these neurons — via intracellular or extracellular transport — directly into brain tissue.

Trigeminal nerve pathway: The trigeminal nerve (CN V) has branches in the nasal mucosa. Molecules can travel along these nerve fibers to the brainstem and from there distribute throughout the CNS via cerebrospinal fluid.

Transit time: Studies with radiolabeled peptides show brain concentrations peaking 15–30 minutes after intranasal administration — rapid compared to systemic routes.

Advantages over injection

• BBB bypass: Direct nose-to-brain transport avoids the blood-brain barrier entirely
• Non-invasive: No needles, no injection-site reactions
• Rapid CNS onset: Brain concentrations achieved in minutes
• Reduced systemic exposure: More drug reaches the brain, less circulates peripherally
• Self-administration convenience: Simple spray devices

Limitations

• Variable absorption: Depends on nasal congestion, mucus, spray technique
• Limited dose capacity: The nasal cavity can only absorb ~100–200 μL per nostril per dose
• Mucosal irritation: Some peptides or preservatives can irritate nasal tissue
• Not suitable for all peptides: Large peptides (>40 kDa) have poor nasal absorption

Which peptides work intranasally?

Established intranasal peptides

Semax (MEHFPGP): The prototypical intranasal peptide. Developed in Russia specifically for nasal administration, with decades of clinical use. Enhances BDNF expression, modulates serotonin/dopamine, and provides nootropic and neuroprotective effects. Available commercially as a 0.1% or 1% nasal solution in Russia.

Selank (TKPRPGP): An anxiolytic peptide analog of tuftsin, also developed for intranasal use. Modulates GABA-ergic signaling and reduces anxiety without sedation. Used clinically in Russia as a nasal spray.

NA-Selank-Amidate: A modified version of Selank with enhanced stability (N-acetylation + C-terminal amidation). The modifications increase resistance to aminopeptidase degradation, extending activity duration.

Oxytocin: Used intranasally in research settings for social bonding, trust, and anxiety studies. FDA-approved Syntocinon nasal spray (now discontinued) demonstrated clinical feasibility.

DSIP (Delta Sleep-Inducing Peptide): While traditionally administered IV or SubQ, intranasal DSIP formulations exist for sleep induction.

Peptides sometimes used intranasally (less established)

• BPC-157: Some users prepare intranasal BPC-157 for cognitive/neurological applications, though subcutaneous remains the standard route
• Epithalon: Occasionally used intranasally; the standard route is subcutaneous
• GHK-Cu: Topical nasal use for sinus health; not a brain-targeting strategy

Preparing peptide nasal sprays

Equipment needed

1. Nasal spray bottle: Metered-dose pump bottles (typically 0.1 mL per spray). Amber glass or HDPE plastic. Sterile.
2. Bacteriostatic water: Preserved with 0.9% benzyl alcohol (standard reconstitution vehicle)
3. Peptide vial: Lyophilized peptide in sealed sterile vial
4. Insulin syringe: For precise volume measurement during reconstitution
5. Alcohol swabs: For vial septum sterilization

Preparation steps

Step 1: Calculate concentration

Determine the desired dose per spray and work backward:

• Standard spray bottle delivers 0.1 mL (100 μL) per actuation
• If target dose = 200 mcg per spray and bottle delivers 0.1 mL per spray:
• Required concentration = 200 mcg / 0.1 mL = 2 mg/mL

Step 2: Reconstitute the peptide

For a 10 mg vial at 2 mg/mL target concentration:

• Add 5 mL of bacteriostatic water to the vial
• Direct water down the side of the vial (never spray directly onto the powder)
• Gently swirl — do not shake

Step 3: Transfer to spray bottle

• Draw reconstituted solution from the vial with syringe
• Transfer to sterile nasal spray bottle
• Prime the pump (typically 3–5 actuations until consistent spray)

Stability considerations

• Refrigeration required: Reconstituted peptide nasal sprays should be stored at 2–8°C
• Use within 30 days: Bacteriostatic water preserves against microbial growth but peptide stability degrades over time
• Avoid contamination: Don't touch the spray tip to nasal mucosa; keep the cap on between uses

Dosing and technique

Optimal spray technique

1. Clear nasal passages: Blow nose gently before dosing
2. Head position: Slightly tilted forward (not back — you don't want solution draining to the throat)
3. Aim: Direct spray toward the upper-outer nasal cavity (toward the olfactory region, not the septum)
4. Breathe in gently: A slow, gentle inhale through the nose during spray — not a forceful sniff
5. Hold briefly: Don't blow nose for 5–10 minutes after application
6. Alternate nostrils: If dosing multiple sprays, alternate between nostrils

Common dosing ranges

Peptide	Typical Nasal Dose	Frequency	Notes
Semax 0.1%	200–600 mcg	2–3× daily	Standard nootropic dose
Semax 1%	1000–3000 mcg	1–2× daily	High-dose neuroprotective
Selank	200–400 mcg	2–3× daily	Anxiolytic dose
NA-Selank-Amidate	100–300 mcg	1–2× daily	Enhanced stability version
Oxytocin	20–40 IU	Single dose	Research protocol dose
DSIP	100–300 mcg	Pre-sleep	Sleep induction

Factors affecting absorption

Enhancers:

• Clear nasal passages (no congestion)
• Proper spray technique (upper-lateral targeting)
• Consistent pH of solution (nasal pH ~5.5–6.5)
• Absorption enhancers (chitosan, cyclodextrins — used in some commercial formulations)

Reducers:

• Nasal congestion (reduces mucosal contact area)
• Thick mucus (barrier to absorption)
• Rapid mucociliary clearance (solution swept to pharynx before absorption)
• Solution draining to throat (lost to GI degradation)

Safety considerations

Nasal tissue health

• Benzyl alcohol sensitivity: Some individuals experience burning or irritation from the preservative in bacteriostatic water. Preservative-free saline can be used for single-dose preparations
• Chronic use: Long-term daily intranasal peptide use has not been associated with significant mucosal damage in published Semax/Selank literature (years of Russian clinical use)
• Infection risk: Maintain sterile technique; contaminated spray bottles can introduce bacteria to nasal passages

Systemic absorption

Intranasal administration does produce some systemic absorption (through nasal mucosal blood vessels). This is typically lower than subcutaneous dosing but not negligible. Peptides intended only for local nasal effect may still produce systemic concentrations.

Medications and interactions

• Nasal decongestant sprays (oxymetazoline) reduce mucosal blood flow and may alter peptide absorption
• Nasal corticosteroids (fluticasone) thin the mucosa — theoretical impact on absorption
• Time peptide sprays at least 15 minutes apart from other nasal medications

When to choose intranasal vs. subcutaneous

Choose intranasal when:

• The target is the CNS (nootropic, anxiolytic, neuroprotective goals)
• The peptide has established nasal pharmacokinetics (Semax, Selank, Oxytocin)
• The user prefers non-invasive administration
• Systemic exposure should be minimized

Choose subcutaneous when:

• The target is peripheral tissue (injury, gut, joints)
• The peptide is too large for nasal absorption
• Precise systemic dosing is important
• The peptide has no nasal bioavailability data

For peptides like BPC-157 that are used for both peripheral healing and potential CNS effects, the route should match the indication: subcutaneous near an injury site for musculoskeletal healing, intranasal (investigational) for neurological applications.